Skip to main content
Equibles
AMLX logo

AMLX · Amylyx Pharmaceuticals, Inc.

Track AMLX — free

Use AMLX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AMLX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$21.63 -0.85 (-3.78%) At close · Aug 14
Market Cap
$2.41B
Shares
111.42M

Amylyx Pharmaceuticals, Inc. Earnings Call Transcripts

Every quarterly earnings call for Amylyx Pharmaceuticals, Inc. (AMLX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲21.1% $345,000 −$53.76M '22 Q3 22-11-10 · $71.43M $1.57M '23 Q1 23-05-11 · $98.22M $22.07M '23 Q2 23-08-10 ▲29666.1% $102.69M $20.89M '23 Q3 23-11-09 · $108.45M $4.73M '23 Q4 24-02-22 ▲24.1% $88.64M −$118.79M '24 Q1 24-05-09 ▼101% $ −$72.70M '24 Q2 24-08-08 ▼99.6% $416,000 −$72.70M '24 Q3 24-11-07 ▼100.6% $ −$37.55M '24 Q4 25-03-04 ▼100% $ −$35.91M '25 Q1 25-05-08 · $ −$41.44M '25 Q2 25-08-07 ▼100% $ −$34.39M '25 Q3 25-11-06 LATEST · $ −$33.00M '25 Q4 26-03-03
Earnings call
FY26 · Q2
2026-08-06
Amylyx Pharmaceuticals, Inc. Q2 FY2026 Earnings Call
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Amylyx Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone AMX0114 in ALS (LUMINA trial) Avexitide pivotal LUCIDITY Phase III trial Commercial launch readiness for avexitide
Diluted EPS
$-0.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Amylyx Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone ALS program AMX114 / LUMINA trial PBH unmet need and market opportunity Avexatide pivotal Phase III LUCIDITY trial
Revenue
$*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Amylyx Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Positive tone Avexitide LUCIDITY Phase III Trial AMX0114 in ALS (LUMINA Trial) Regulatory Engagement and Trial Design
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.37
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Amylyx Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone Avexitide / PBH lead program AMX0114 in ALS AMX0035 in PSP (ORION trial)
Revenue
$
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Amylyx Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone Avexitide / LUCIDITY Phase 3 in post-bariatric hypoglycemia AMX0114 in ALS (LUMINA Phase 1) AMX0035 in progressive supranuclear palsy (ORION)
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Amylyx Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone Avexitide LUCIDITY Phase III in PBH AMX0114 in ALS (LUMINA) AMX0035 in PSP (ORION)
Revenue
$*
▼ 100.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Amylyx Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Positive tone Avexitide Phase III in PBH AMX0114 in ALS (LUMINA) AMX0035 in PSP (ORION)
Revenue
$416,000
▼ 99.6% YoY
Diluted EPS
$-1.07
▼ 456.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Amylyx Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Positive tone Avexitide for post-bariatric hypoglycemia (PBH) AMX0114 in ALS Regulatory engagement and trial design
Revenue
$
▼ 101% YoY
Diluted EPS
$-1.07
▼ 445.2% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Amylyx Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Cautious tone AMX0114 / Calpain-2 ALS antisense program PHOENIX trial failure and restructuring PSP (AMX0035) program
Revenue
$88.64M
▲ 24.1% YoY
Diluted EPS
$-1.75
▼ 8850% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Amylyx Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Positive tone PHOENIX Phase 3 trial readout RELYVRIO commercial launch and growth initiatives Pipeline expansion in neurodegenerative diseases
Revenue
$108.45M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Amylyx Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$102.69M
▲ 29666.1% YoY
Diluted EPS
$0.30
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Amylyx Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$98.22M
Diluted EPS
$0.31
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Amylyx Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$71.43M
Diluted EPS
$0.02
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Amylyx Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Amylyx Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$345,000
▲ 21.1% YoY
Diluted EPS
$-0.92
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 earnings calls
Key facts CIK 1658551 CUSIP 03237H101 13F (30d) 199 filings 197 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)